Compare Stocks: VRCA, SIGA, IKT, and SLGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$1.50 -2.9%	$2.06	$1.39 ▼ $2.61	$209.30M	0.89	1.06 million shs	158,720 shs
SIGA Siga Technologies	$3.05 +3.2%	$3.18	$2.83 ▼ $8.46	$218.78M	1.04	604,307 shs	189,807 shs
SLGL Sol-Gel Technologies	$65.32 -0.6%	$68.80	$28.81 ▼ $97.97	$214.53M	1.14	41,131 shs	11,285 shs
VRCA Verrica Pharmaceuticals	$3.40 +5.9%	$4.37	$3.20 ▼ $9.82	$58.15M	1.6	86,860 shs	27,830 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	-0.65%	+1.32%	-23.00%	-36.89%	+4.76%
SIGA Siga Technologies	-2.96%	-6.35%	-12.72%	-8.95%	-64.37%
SLGL Sol-Gel Technologies	-3.89%	-5.66%	-8.76%	-22.26%	+84.83%
VRCA Verrica Pharmaceuticals	-4.18%	-6.14%	-26.71%	-40.67%	-11.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$1.50 -2.9%	$2.06	$1.39 ▼ $2.61	$209.30M	0.89	1.06 million shs	158,720 shs
SIGA Siga Technologies	$3.05 +3.2%	$3.18	$2.83 ▼ $8.46	$218.78M	1.04	604,307 shs	189,807 shs
SLGL Sol-Gel Technologies	$65.32 -0.6%	$68.80	$28.81 ▼ $97.97	$214.53M	1.14	41,131 shs	11,285 shs
VRCA Verrica Pharmaceuticals	$3.40 +5.9%	$4.37	$3.20 ▼ $9.82	$58.15M	1.6	86,860 shs	27,830 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	-0.65%	+1.32%	-23.00%	-36.89%	+4.76%
SIGA Siga Technologies	-2.96%	-6.35%	-12.72%	-8.95%	-64.37%
SLGL Sol-Gel Technologies	-3.89%	-5.66%	-8.76%	-22.26%	+84.83%
VRCA Verrica Pharmaceuticals	-4.18%	-6.14%	-26.71%	-40.67%	-11.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKT Inhibikase Therapeutics	2.90	Moderate Buy	$4.75	217.73% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A
SLGL Sol-Gel Technologies	3.00	Buy	$197.50	202.34% Upside
VRCA Verrica Pharmaceuticals	2.40	Hold	$12.67	272.66% Upside

Current Analyst Ratings Breakdown

Latest VRCA, SIGA, IKT, and SLGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
10/15/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SLGL Sol-Gel Technologies	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/14/2026	SLGL Sol-Gel Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight
10/13/2026	VRCA Verrica Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/13/2026	IKT Inhibikase Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Neutral	$1.50
10/13/2026	IKT Inhibikase Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Hold	$1.50
10/6/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/1/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/27/2026	VRCA Verrica Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$9.00
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$2.30 per share	N/A
SIGA Siga Technologies	$53.66M	4.08	$0.31 per share	9.94	$2.78 per share	1.10
SLGL Sol-Gel Technologies	$19.39M	11.02	N/A	N/A	$8.19 per share	7.98
VRCA Verrica Pharmaceuticals	$35.58M	1.64	N/A	N/A	$1.55 per share	2.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/9/2026 (Estimated)
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	11/19/2026 (Estimated)
VRCA Verrica Pharmaceuticals	-$17.89M	-$1.67	N/A	N/A	N/A	-102.84%	-407.11%	-70.17%	11/13/2026 (Estimated)

Latest VRCA, SIGA, IKT, and SLGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/19/2026	Q3 2026	SLGL Sol-Gel Technologies	-$2.0745	N/A	N/A	N/A	$0.15 million	N/A
11/13/2026	Q3 2026	VRCA Verrica Pharmaceuticals	-$0.45	N/A	N/A	N/A	$6.20 million	N/A
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKT Inhibikase Therapeutics	N/A	15.82	15.82
SIGA Siga Technologies	N/A	21.72	16.48
SLGL Sol-Gel Technologies	N/A	10.37	10.37
VRCA Verrica Pharmaceuticals	0.18	1.45	1.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKT Inhibikase Therapeutics	3.81%
SIGA Siga Technologies	55.40%
SLGL Sol-Gel Technologies	26.18%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
IKT Inhibikase Therapeutics	7.10%
SIGA Siga Technologies	2.73%
SLGL Sol-Gel Technologies	66.51%
VRCA Verrica Pharmaceuticals	52.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
SIGA Siga Technologies	49	71.85 million	69.89 million	Optionable
SLGL Sol-Gel Technologies	28	3.27 million	1.10 million	No Data
VRCA Verrica Pharmaceuticals	76	17.18 million	8.09 million	Optionable

VRCA, SIGA, IKT, and SLGL Headlines

Recent News About These Companies

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Consensus Price Target of $12.67 According to Brokerages

November 3 at 4:28 AM | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Down 2% - What's Next?

October 30, 2026 | marketbeat.com

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

October 22, 2026 | globenewswire.com

Lake Street sets USD 9.00 target for Verrica Pharmaceuticals stock

October 18, 2026 | ad-hoc-news.deA

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Target Price of $12.67

October 9, 2026 | marketbeat.com

Lake Street Keeps Their Buy Rating on Verrica Pharmaceuticals (VRCA)

October 6, 2026 | theglobeandmail.com

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

September 30, 2026 | globenewswire.com

Verrica Pharmaceuticals stock trades at USD 4.10

September 22, 2026 | ad-hoc-news.deA

Verrica Pharmaceuticals stock holds steady as investors watch latest clinical and earnings signals

September 21, 2026 | ad-hoc-news.deA

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

September 10, 2026 | globenewswire.com

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...

August 27, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026 | globenewswire.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 Shares

August 19, 2026 | insidertrades.com

Verrica (VRCA) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026 | manilatimes.netM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026 | finance.yahoo.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...

July 21, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, SIGA, IKT, and SLGL Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

$1.50 -0.05 (-2.92%)

As of 12:56 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Siga Technologies NASDAQ:SIGA

$3.04 +0.10 (+3.22%)

As of 12:57 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Sol-Gel Technologies NASDAQ:SLGL

$65.32 -0.37 (-0.56%)

As of 12:58 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Verrica Pharmaceuticals NASDAQ:VRCA

$3.40 +0.19 (+5.89%)

As of 12:58 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRCA, SIGA, IKT, and SLGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRCA, SIGA, IKT, and SLGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRCA, SIGA, IKT, and SLGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, SIGA, IKT, and SLGL Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

Siga Technologies NASDAQ:SIGA

Sol-Gel Technologies NASDAQ:SLGL

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRCA, SIGA, IKT, and SLGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRCA, SIGA, IKT, and SLGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRCA, SIGA, IKT, and SLGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, SIGA, IKT, and SLGL Company Descriptions

Inhibikase Therapeutics NASDAQ:IKT

Siga Technologies NASDAQ:SIGA

Sol-Gel Technologies NASDAQ:SLGL

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools